Travere Therapeutics/$TVTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
- Ticker
- $TVTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 497
- Headquarters
- San Diego, United States
- Website
- travere.com
TVTX Metrics
BasicAdvanced
$5.4B
-
-$0.48
1.04
-
Price and volume
Market cap
$5.4B
Beta
1.04
52-week high
$68.73
52-week low
$22.59
Average daily volume
1.5M
Financial strength
Current ratio
4.046
Quick ratio
3.763
Long term debt to equity
24.906
Total debt to equity
25.157
Interest coverage (TTM)
-4.27%
Profitability
EBITDA (TTM)
22.913
Gross margin (TTM)
59.21%
Net profit margin (TTM)
-7.35%
Operating margin (TTM)
-6.84%
Effective tax rate (TTM)
-0.90%
Revenue per employee (TTM)
$1,190,000
Management effectiveness
Return on assets (TTM)
-3.73%
Return on equity (TTM)
-236.35%
Valuation
Price to revenue (TTM)
8.77
Price to book
218.33
Price to tangible book (TTM)
-50.04
Price to free cash flow (TTM)
342.004
Free cash flow yield (TTM)
0.29%
Free cash flow per share (TTM)
0.166
Growth
Revenue change (TTM)
77.12%
Earnings per share change (TTM)
-76.17%
3-year revenue growth (CAGR)
69.94%
10-year revenue growth (CAGR)
17.22%
3-year earnings per share growth (CAGR)
-52.74%
10-year earnings per share growth (CAGR)
-15.14%
What the Analysts think about TVTX
Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.
Analyst projections of the future price of Travere Therapeutics stock.
Bulls say / Bears say
FILSPARI is showing strong commercial momentum: US sales reached $141.1 million in Q2 2026, up 96% year on year, while the FSGS launch helped generate 2,012 new patient start forms. FDA approval for FSGS gives the drug a second indication and expands Travere’s addressable market. (Travere Therapeutics, Reuters)
Travere is strengthening FILSPARI’s protection from competition. Newly allowed US method-of-use patents are expected to cover use in IgAN and FSGS through October 2037, subject to issuance, scope, validity and listing. (Travere Therapeutics, Travere Therapeutics)
The pipeline could add growth beyond FILSPARI. Pegtibatinase is in a pivotal Phase 3 study for classical homocystinuria, while the newly licensed civorebrutinib offers an additional opportunity across immune-mediated rare kidney diseases. (Travere Therapeutics, Travere Therapeutics)
Travere remains loss-making despite rapid sales growth. Q2 2026 brought a $34.8 million GAAP loss, while higher research and development and selling costs show that the FSGS launch and pipeline are consuming substantial cash. (Travere Therapeutics, Travere Therapeutics)
The IgAN market is becoming more competitive, and management expects FILSPARI’s gross-to-net discounts to rise in the second half as FSGS brings greater CMS exposure. That could limit how much of the prescription growth converts into net revenue. (The Motley Fool, Travere Therapeutics)
The diversification story is still several years away from proof. Pegtibatinase’s Phase 3 topline data are not expected until the second half of 2027, and civorebrutinib is a newly in-licensed programme, leaving FILSPARI as the main near-term commercial engine. (Travere Therapeutics, Travere Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 28 Sept 2026.
TVTX Financial Performance
Revenues and expenses
TVTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
TVTX News
AllArticlesVideos
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Business Wire12 hours ago
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
Business Wire1 week ago
Travere Therapeutics Announces Planned Chief Executive Officer Transition
Business Wire2 weeks ago
Funds containing TVTX
AllUSDGBPEUR
Fund name | Fund size | $TVTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.36% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.36% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.18% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.18% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.